Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASH Preview: Researchers Chase Winning Combination In Frontline Myeloma

Executive Summary

At this year's American Society of Hematology meeting, scientists will present data suggesting a cocktail of Revlimid, Velcade and dexamethasone could emerge as the backbone of frontline therapy for multiple myeloma
Advertisement

Related Content

Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype
Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype
Celgene's Revlimid Thrives As First-Line Multiple Myeloma Treatment
FDA Approves Genzyme’s Mozobil For Bone Marrow Transplant Prep
ASH Data Give Millennium’s Velcade A Boost, Raise Bar For Competitors
ASH Data Give Millennium’s Velcade A Boost, Raise Bar For Competitors
Closing The Gap On Velcade, Proteolix Bags $79M In Series C
Velcade Wins FDA Clearance In First-Line MM
Advertisement
UsernamePublicRestriction

Register

PS050382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel